Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials
We surveyed randomized controlled trials (RCTs) examining the efficacy and safety of anifrolumab 300 mg in patients with active systemic lupus erythematosus (SLE) despite receiving standard therapy, using MEDLINE, EMBASE, the Cochrane Controlled Trials Register, and manual searches. Meta-analysis pe...
Gespeichert in:
| Veröffentlicht in: | Zeitschrift für Rheumatologie 2021-12, Vol.80 (10), p.988-994 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 994 |
|---|---|
| container_issue | 10 |
| container_start_page | 988 |
| container_title | Zeitschrift für Rheumatologie |
| container_volume | 80 |
| creator | Lee, Y. H. Song, G. G. |
| description | We surveyed randomized controlled trials (RCTs) examining the efficacy and safety of anifrolumab 300 mg in patients with active systemic lupus erythematosus (SLE) despite receiving standard therapy, using MEDLINE, EMBASE, the Cochrane Controlled Trials Register, and manual searches. Meta-analysis performed to determine treatment efficacy and safety outcomes of three RCTs (459 patients and 468 controls) revealed that the BICLA responses were significantly higher in the anifrolumab group than in the placebo group (OR = 2.071, 95%CI 1.575–2.725,
p
|
| doi_str_mv | 10.1007/s00393-020-00928-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2463099808</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2463099808</sourcerecordid><originalsourceid>FETCH-LOGICAL-c324t-4a65325a7eef124e786b7158be85caee130af43d245e36fff2ef32461082f2d73</originalsourceid><addsrcrecordid>eNp9kLtOxDAQRS0EEsvjB6hc0hjGryRLhxAvCYkGasubHUNQEi8eB2n5Gr6FL8PLUlPdKc69Ix3GTiScSYD6nAD0XAtQIADmqhH1DptJo62QysIum4E2IGRj7T47IHoDkKYyZsY-LscupNhPg1_wEBPPr8hzQp8HHDOPgfs2dx_IaU0Zh67l_bSaiGNaF3LwOdJEF9x_fw2YvfCj79fU0aaY_LiMQ_eJS97GMZcnfTlz6nxPR2wvlMDjvzxkzzfXT1d34uHx9v7q8kG0WpksjK-sVtbXiEEqg3VTLWppmwU2tvWIUoMPRi-VsairEILCUIqVhEYFtaz1ITvd7q5SfJ-Qshs6arHv_YhxIldYDfN5A01B1RZtUyRKGNwqdYNPayfBbSS7rWRXJLtfyW6zr7clKvD4gsm9xSkVCfRf6wc9J4MP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2463099808</pqid></control><display><type>article</type><title>Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials</title><source>SpringerLink Journals</source><creator>Lee, Y. H. ; Song, G. G.</creator><creatorcontrib>Lee, Y. H. ; Song, G. G.</creatorcontrib><description>We surveyed randomized controlled trials (RCTs) examining the efficacy and safety of anifrolumab 300 mg in patients with active systemic lupus erythematosus (SLE) despite receiving standard therapy, using MEDLINE, EMBASE, the Cochrane Controlled Trials Register, and manual searches. Meta-analysis performed to determine treatment efficacy and safety outcomes of three RCTs (459 patients and 468 controls) revealed that the BICLA responses were significantly higher in the anifrolumab group than in the placebo group (OR = 2.071, 95%CI 1.575–2.725,
p
< 0.001). Steroid reduction and CLASI reduction were also significantly higher in the anifrolumab group than in the placebo group (OR = 1.811, 95%CI = 1.308–2.506,
p
< 0.001; OR = 2.245, 95%CI = 1.437–3.506,
p
< 0.001). Compared with placebo, anifrolumab significantly increased the SRI7 and SRI8 responses in SLE patients (OR = 1.866, 95%CI = 1.372–2.536,
p
< 0.001; OR = 1.925, 95%CI = 1.387–2.672,
p
< 0.001). The SRI4, 5, and 6 responses also tended to be higher in the anifrolumab group than in the placebo group. Adverse event incidence was significantly higher in the anifrolumab group than in the placebo group (OR = 1.815, 95%CI = 1.262–2.611,
p
= 0.001); serious adverse events were significantly lower in the anifrolumab group than in the placebo group (OR = 0.679, 95%CI = 0.468–0.986,
p
= 0.042). Herpes zoster infection was significantly higher in the anifrolumab group than in the placebo group (OR = 4.089, 95%CI = 1.750–9.522,
p
= 0.001). Anifrolumab is effective for treating active SLE. However, anifrolumab increased the incidence of herpes zoster infection compared with placebo.</description><identifier>ISSN: 0340-1855</identifier><identifier>EISSN: 1435-1250</identifier><identifier>DOI: 10.1007/s00393-020-00928-7</identifier><language>eng</language><publisher>Heidelberg: Springer Medizin</publisher><subject>Immunology ; Internal Medicine ; Laboratory Medicine ; Medicine ; Medicine & Public Health ; Originalien ; Orthopedics ; Rheumatology</subject><ispartof>Zeitschrift für Rheumatologie, 2021-12, Vol.80 (10), p.988-994</ispartof><rights>Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c324t-4a65325a7eef124e786b7158be85caee130af43d245e36fff2ef32461082f2d73</citedby><cites>FETCH-LOGICAL-c324t-4a65325a7eef124e786b7158be85caee130af43d245e36fff2ef32461082f2d73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00393-020-00928-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00393-020-00928-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Lee, Y. H.</creatorcontrib><creatorcontrib>Song, G. G.</creatorcontrib><title>Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials</title><title>Zeitschrift für Rheumatologie</title><addtitle>Z Rheumatol</addtitle><description>We surveyed randomized controlled trials (RCTs) examining the efficacy and safety of anifrolumab 300 mg in patients with active systemic lupus erythematosus (SLE) despite receiving standard therapy, using MEDLINE, EMBASE, the Cochrane Controlled Trials Register, and manual searches. Meta-analysis performed to determine treatment efficacy and safety outcomes of three RCTs (459 patients and 468 controls) revealed that the BICLA responses were significantly higher in the anifrolumab group than in the placebo group (OR = 2.071, 95%CI 1.575–2.725,
p
< 0.001). Steroid reduction and CLASI reduction were also significantly higher in the anifrolumab group than in the placebo group (OR = 1.811, 95%CI = 1.308–2.506,
p
< 0.001; OR = 2.245, 95%CI = 1.437–3.506,
p
< 0.001). Compared with placebo, anifrolumab significantly increased the SRI7 and SRI8 responses in SLE patients (OR = 1.866, 95%CI = 1.372–2.536,
p
< 0.001; OR = 1.925, 95%CI = 1.387–2.672,
p
< 0.001). The SRI4, 5, and 6 responses also tended to be higher in the anifrolumab group than in the placebo group. Adverse event incidence was significantly higher in the anifrolumab group than in the placebo group (OR = 1.815, 95%CI = 1.262–2.611,
p
= 0.001); serious adverse events were significantly lower in the anifrolumab group than in the placebo group (OR = 0.679, 95%CI = 0.468–0.986,
p
= 0.042). Herpes zoster infection was significantly higher in the anifrolumab group than in the placebo group (OR = 4.089, 95%CI = 1.750–9.522,
p
= 0.001). Anifrolumab is effective for treating active SLE. However, anifrolumab increased the incidence of herpes zoster infection compared with placebo.</description><subject>Immunology</subject><subject>Internal Medicine</subject><subject>Laboratory Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Originalien</subject><subject>Orthopedics</subject><subject>Rheumatology</subject><issn>0340-1855</issn><issn>1435-1250</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kLtOxDAQRS0EEsvjB6hc0hjGryRLhxAvCYkGasubHUNQEi8eB2n5Gr6FL8PLUlPdKc69Ix3GTiScSYD6nAD0XAtQIADmqhH1DptJo62QysIum4E2IGRj7T47IHoDkKYyZsY-LscupNhPg1_wEBPPr8hzQp8HHDOPgfs2dx_IaU0Zh67l_bSaiGNaF3LwOdJEF9x_fw2YvfCj79fU0aaY_LiMQ_eJS97GMZcnfTlz6nxPR2wvlMDjvzxkzzfXT1d34uHx9v7q8kG0WpksjK-sVtbXiEEqg3VTLWppmwU2tvWIUoMPRi-VsairEILCUIqVhEYFtaz1ITvd7q5SfJ-Qshs6arHv_YhxIldYDfN5A01B1RZtUyRKGNwqdYNPayfBbSS7rWRXJLtfyW6zr7clKvD4gsm9xSkVCfRf6wc9J4MP</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Lee, Y. H.</creator><creator>Song, G. G.</creator><general>Springer Medizin</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20211201</creationdate><title>Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials</title><author>Lee, Y. H. ; Song, G. G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c324t-4a65325a7eef124e786b7158be85caee130af43d245e36fff2ef32461082f2d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Immunology</topic><topic>Internal Medicine</topic><topic>Laboratory Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Originalien</topic><topic>Orthopedics</topic><topic>Rheumatology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Y. H.</creatorcontrib><creatorcontrib>Song, G. G.</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Zeitschrift für Rheumatologie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Y. H.</au><au>Song, G. G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials</atitle><jtitle>Zeitschrift für Rheumatologie</jtitle><stitle>Z Rheumatol</stitle><date>2021-12-01</date><risdate>2021</risdate><volume>80</volume><issue>10</issue><spage>988</spage><epage>994</epage><pages>988-994</pages><issn>0340-1855</issn><eissn>1435-1250</eissn><abstract>We surveyed randomized controlled trials (RCTs) examining the efficacy and safety of anifrolumab 300 mg in patients with active systemic lupus erythematosus (SLE) despite receiving standard therapy, using MEDLINE, EMBASE, the Cochrane Controlled Trials Register, and manual searches. Meta-analysis performed to determine treatment efficacy and safety outcomes of three RCTs (459 patients and 468 controls) revealed that the BICLA responses were significantly higher in the anifrolumab group than in the placebo group (OR = 2.071, 95%CI 1.575–2.725,
p
< 0.001). Steroid reduction and CLASI reduction were also significantly higher in the anifrolumab group than in the placebo group (OR = 1.811, 95%CI = 1.308–2.506,
p
< 0.001; OR = 2.245, 95%CI = 1.437–3.506,
p
< 0.001). Compared with placebo, anifrolumab significantly increased the SRI7 and SRI8 responses in SLE patients (OR = 1.866, 95%CI = 1.372–2.536,
p
< 0.001; OR = 1.925, 95%CI = 1.387–2.672,
p
< 0.001). The SRI4, 5, and 6 responses also tended to be higher in the anifrolumab group than in the placebo group. Adverse event incidence was significantly higher in the anifrolumab group than in the placebo group (OR = 1.815, 95%CI = 1.262–2.611,
p
= 0.001); serious adverse events were significantly lower in the anifrolumab group than in the placebo group (OR = 0.679, 95%CI = 0.468–0.986,
p
= 0.042). Herpes zoster infection was significantly higher in the anifrolumab group than in the placebo group (OR = 4.089, 95%CI = 1.750–9.522,
p
= 0.001). Anifrolumab is effective for treating active SLE. However, anifrolumab increased the incidence of herpes zoster infection compared with placebo.</abstract><cop>Heidelberg</cop><pub>Springer Medizin</pub><doi>10.1007/s00393-020-00928-7</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-1855 |
| ispartof | Zeitschrift für Rheumatologie, 2021-12, Vol.80 (10), p.988-994 |
| issn | 0340-1855 1435-1250 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2463099808 |
| source | SpringerLink Journals |
| subjects | Immunology Internal Medicine Laboratory Medicine Medicine Medicine & Public Health Originalien Orthopedics Rheumatology |
| title | Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T08%3A50%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anifrolumab%20for%20the%20treatment%20of%20active%20systemic%20lupus%20erythematosus:%20a%C2%A0meta-analysis%20of%20randomized%20controlled%20trials&rft.jtitle=Zeitschrift%20f%C3%BCr%20Rheumatologie&rft.au=Lee,%20Y.%20H.&rft.date=2021-12-01&rft.volume=80&rft.issue=10&rft.spage=988&rft.epage=994&rft.pages=988-994&rft.issn=0340-1855&rft.eissn=1435-1250&rft_id=info:doi/10.1007/s00393-020-00928-7&rft_dat=%3Cproquest_cross%3E2463099808%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2463099808&rft_id=info:pmid/&rfr_iscdi=true |